| Size | Price | Stock | Qty |
|---|---|---|---|
| 500mg |
|
||
| 1g |
|
||
| Other Sizes |
| Targets |
L-Butyrine does not have a specific pharmacological target; it is a non-proteinogenic amino acid that can be used by nonribosomal peptide synthases. It inhibits LPS-induced NO production in isolated mouse BMDMs at 0.1 and 1 mM.
|
|---|---|
| ln Vitro |
In vitro, L-butyrine inhibits LPS-induced NO production in isolated mouse bone marrow-derived macrophages (BMDMs) at 0.1 and 1 mM. It serves as a chiral building block in organic synthesis.
|
| ln Vivo |
In vivo, L-butyrine is a non-proteinogenic amino acid that can be found in the human kidney, liver tissues, and most biofluids or excreta. Levels are elevated in patients with Reye's syndrome, tyrosinemia, homocystinuria, and ornithine aminotransferase deficiency.
|
| Enzyme Assay |
In vitro enzyme/receptor binding assays for L-butyrine typically involve evaluating its role as a substrate or inhibitor of enzymes such as aminotransferases. Activity is measured by monitoring the conversion of L-butyrine to its corresponding keto acid.
|
| Cell Assay |
For in vitro cell-based assays, L-butyrine is dissolved in aqueous buffers and applied to cultured cells such as macrophages at concentrations ranging from 0.1-10 mM. Effects on NO production, cell viability, or metabolic pathways are assessed after 24-72 hours of treatment.
|
| Animal Protocol |
In vivo animal studies for L-butyrine are typically metabolic or toxicological studies. The compound is administered orally or intraperitoneally at doses ranging from 10-100 mg/kg.
|
| ADME/Pharmacokinetics |
L-Butyrine has a molecular weight of 103.12 g/mol. It is a non-proteinogenic amino acid and a member of the class of compounds known as L-alpha-amino acids.
|
| Toxicity/Toxicokinetics |
L-Butyrine is considered to have low toxicity. It is a naturally occurring amino acid found in the human body. No significant toxicity has been reported at physiological concentrations.
|
| References | |
| Additional Infomation |
L-α-aminobutyric acid (GABA) is the optically active form of α-aminobutyric acid with the L-configuration. It is a human metabolite. It is an α-aminobutyric acid and a non-protein L-α-amino acid. It is the conjugate acid of L-2-aminobutyric acid. It is the enantiomer of D-α-aminobutyric acid. It is the zwitterion tautomer of L-α-aminobutyric acid. L-2-aminobutyric acid has been reported to exist in Homo sapiens, cycads, and Caenorhabditis elegans, and relevant data are available.
L-Butyrine is used in pharmaceutical research as an intermediate for synthesizing biologically active compounds, including neuroactive agents and metabolic modulators. It is also used as a chiral building block in organic synthesis. |
| Molecular Formula |
C4H9NO2
|
|---|---|
| Molecular Weight |
103.12
|
| Exact Mass |
103.063
|
| CAS # |
1492-24-6
|
| Related CAS # |
H-Abu-OH-d3;929202-07-3;H-Abu-OH-d6;1276197-51-3;H-Abu-OH-d2;352431-37-9
|
| PubChem CID |
80283
|
| Appearance |
White to off-white solid powder
|
| Density |
1.2300
|
| Boiling Point |
215.2±23.0 °C at 760 mmHg
|
| Melting Point |
300ºC
|
| Flash Point |
83.9±22.6 °C
|
| Vapour Pressure |
0.1±0.9 mmHg at 25°C
|
| Index of Refraction |
1.462
|
| LogP |
-0.15
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
7
|
| Complexity |
72.1
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
CC[C@@H](C(=O)O)N
|
| InChi Key |
QWCKQJZIFLGMSD-VKHMYHEASA-N
|
| InChi Code |
InChI=1S/C4H9NO2/c1-2-3(5)4(6)7/h3H,2,5H2,1H3,(H,6,7)/t3-/m0/s1
|
| Chemical Name |
(2S)-2-aminobutanoic acid
|
| Synonyms |
NSC-97060; NSC 97060; L-Butyrine
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : ~50 mg/mL (~484.87 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 50 mg/mL (484.87 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication.
(Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 9.6974 mL | 48.4872 mL | 96.9744 mL | |
| 5 mM | 1.9395 mL | 9.6974 mL | 19.3949 mL | |
| 10 mM | 0.9697 mL | 4.8487 mL | 9.6974 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
